Nichols, Erin

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study

Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 220

Ethical and responsible use of artificial intelligence in medical education

Sriram, A., Nichols, E., Ganti, L., & Gue, S. (2026) · International Journal of Emergency Medicine

Artificial Intelligence in Healthcare and EducationEthics and Social Impacts of AI

Cited by 0